1. Current Challenges in Cancer Immunotherapy: Multimodal Approaches to Improve Efficacy and Patient Response Rates
   Manpreet Sambi et al, 2019, Journal of Oncology CrossRef
2. Tumour growth and immune evasion as targets for a new strategy in advanced cancer
   Andrea Nicolini et al, 2018 CrossRef
3. European Patent in Immunoncology: From Immunological Principles of Implantation to Cancer Treatment
   Franziska M. Würfel et al, 2019, IJMS CrossRef
4. Facing the future: challenges and opportunities in adoptive T cell therapy in cancer
   Isabelle Magalhaes et al, 2019, Expert Opinion on Biological Therapy CrossRef
5. Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance
   Simon Pernot et al, 2019, Gastric Cancer CrossRef
6. Differential alternative splicing regulation among hepatocellular carcinoma with different risk factors
   Young-Joo Jin et al, 2019, BMC Med Genomics CrossRef
7. null
   Armin Hirbod-Mobarakeh et al, 2020 CrossRef
8. “Metastatic Cancer of Unknown Primary” or “Primary Metastatic Cancer”?
   Stefan Kolling et al, 2020, Front. Oncol. CrossRef
9. Immune profile and immunosurveillance in treatment-naive and neoadjuvantly treated esophageal adenocarcinoma.
   Svenja Wagener-Ryczek et al, 2020, Cancer Immunol Immunother CrossRef
10. Single cell RNA-seq reveals the landscape of tumor and infiltrating immune cells in nasopharyngeal cancer
    Jin Zhao et al, 2020, Cancer Letters CrossRef
11. Classification models for Invasive Ductal Carcinoma Progression, based on gene expression data-trained supervised machine learning
    Shikha Roy et al, 2020, Sci Rep CrossRef
12. Cancer Stem Cells: Devil or Savior—Looking behind the Scenes of Immunotherapy Failure
    Lorenzo Castagnoli et al, 2020, Cells CrossRef
13. Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy
    Alok Kumar et al, 2020 CrossRef
14. Harnessing NK Cell Checkpoint-Modulating Immunotherapies
    Sachin Kumar Singh Chauhan et al, 2020, Cancers CrossRef
15. The Role of the RNA-Binding Protein Family MEX-3 in Tumorigenesis
    Simon Jasinski-Bergner et al, 2020, IJMS CrossRef
16. Molecular and Immunological Characterization of Biliary Tract Cancers: A Paradigm Shift Towards a Personalized Medicine
    Ines Malenica et al, 2020, Cancers CrossRef
17. Joining Forces: Improving Clinical Response to Cellular Immunotherapies with Small-Molecule Inhibitors
    Debottam Sinha et al, 2020, Trends in Molecular Medicine CrossRef
18. The potential use of theranostic bacteria in cancer
    Khalil Azizian et al, 2020, J Cell Physiol CrossRef
19. Anti-tumour effect of the fourth-generation chimeric antigen receptor T cells targeting CD133 against cholangiocarcinoma cells
    Thanich Sangsuwannukul et al, 2020, International Immunopharmacology CrossRef
20. The Role of Antigen Processing and Presentation in Cancer and the Efficacy of Immune Checkpoint Inhibitor Immunotherapy
    Anastasia Mpakali et al, 2021, Cancers CrossRef
21. Mutated clones driving leukemic transformation are already detectable at the single-cell level in CD34-positive cells in the chronic phase of primary myelofibrosis
    Sandra Parenti et al, 2021, npj Precis. Onc. CrossRef
22. Tackling HLA Deficiencies Head on with Oncolytic Viruses
    Kerry Fisher et al, 2021, Cancers CrossRef
23. 'Off-the-shelf’ allogeneic antigen-specific adoptive T-cell therapy for the treatment of multiple EBV-associated malignancies
    Debottam Sinha et al, 2021, J Immunother Cancer CrossRef
24. A Wnt-mediated phenotype switch along the epithelial–mesenchymal axis defines resistance and invasion downstream of ionising radiation in oral squamous cell carcinoma
    Fatemeh Zolghadr et al, 2021, Br J Cancer CrossRef
25. Human leukocyte antigen I is significantly downregulated in patients with myxoid liposarcomas
    Naoki Oike et al, 2021, Cancer Immunol Immunother CrossRef
26. Addressing resistance to immune checkpoint inhibitor therapy: an urgent unmet need
    Siwen Hu-Lieskovan et al, 2021, Future Oncology CrossRef
27. HLA-G 3’UTR Polymorphisms Are Linked to Susceptibility and Survival in Spanish Gastric Adenocarcinoma Patients
    Christian Vaquero-Yuste et al, 2021, Front. Immunol. CrossRef
28. Seeding metastases: The role and clinical utility of circulating tumour cells
    Deep A. Patel et al, 2021, TUB CrossRef
29. Modulation of intrinsic inhibitory checkpoints using nano‐carriers to unleash NK cell activity
    Guy Biber et al, 2021, EMBO Mol Med CrossRef
30. HLA-G/sHLA-G and HLA-G-Bearing Extracellular Vesicles in Cancers: Potential Role as Biomarkers
    Peilong Li et al, 2021, Front. Immunol. CrossRef
31. HLA-G: Too Much or Too Little? Role in Cancer and Autoimmune Disease
    José Manuel Martín-Villa et al, 2022, Front. Immunol. CrossRef
32. Immunomodulatory Potential of Non-Classical HLA-G in Infections including COVID-19 and Parasitic Diseases
    Sajad Rashidi et al, 2022, Biomolecules CrossRef
33. Directing CAR T cells towards the tumor vasculature for the treatment of solid tumors
    Parvin Akbari et al, 2022, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer CrossRef
34. High-Density, Targeted Monitoring of Tyrosine Phosphorylation Reveals Activated Signaling Networks in Human Tumors
    Lauren E. Stopfer et al, 2021 CrossRef
35. null
    Ruchi Shah et al, 2022 CrossRef
36. Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells
    Methi Wathikthinnakon et al, 2022, Sci Rep CrossRef
37. HepG2 Attenuation Induced by RNase A Modulates Gene Profiling and Immunophenotypic Characterization of Some Immune Cells Operating in Cancer Vaccine
    null Fatma F. Abdel Hamid et al, 2018, J. Can. Res. Updates CrossRef
38. null
    Louisa L. Wiede et al, 2022 CrossRef
39. Impact of immune cells on the hallmarks of cancer: A literature review.
    Alexandra C Costa et al, 2021, Crit Rev Oncol Hematol CrossRef
40. TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma
    Vivian Changying Jiang et al, 2022, Mol Cancer CrossRef
41. Mechanisms adopted by cancer cells to escape apoptosis–A review
    SAYEQUA DANDOTI, 2021 CrossRef
42. Chimeric Antigen Receptor (CAR) T-cell Therapy: A New Genetically Engineered Method of Immunotherapy for Cancer
    Arun Kumar Singh et al, 2023, CCDT CrossRef
43. Roles of cancer stem cells in cancer immune surveillance
    Nhat-Chau TRUONG et al, 2023, Minerva Biotechnol Biomol Res CrossRef
44. Melanoma and Human Leukocyte Antigen (HLA): Immunogenicity of 69 HLA Class I Alleles With 11 Antigens Expressed in Melanoma Tumors
    Apostolos P Georgopoulos et al, 2023, Cancer Inform CrossRef
45. Immunobiology of cancer stem cells and their immunoevasion mechanisms
    Havva Marzban et al, 2023, Mol Biol Rep CrossRef
46. HLA‐Ehigh/HLA‐Ghigh/HLA‐IIlow Human iPSC‐Derived Cardiomyocytes Exhibit Low Immunogenicity for Heart Regeneration
    Yi‐Hsien Fang et al, 2023, Adv Healthcare Materials CrossRef
47. The potential roles of gossypol as anticancer agent: advances and future directions
    Danijela Paunovic et al, 2023, Chin Med CrossRef
48. The role of immune checkpoints in antitumor response: a potential antitumor immunotherapy
    Lidy Vannessa Mejía-Guarnizo et al, 2023, Front. Immunol. CrossRef
49. Integrative HLA typing of tumor and adjacent normal tissue can reveal insights into the tumor immune response
    Angelina Sverchkova et al, 2024, BMC Med Genomics CrossRef
50. Exploring novel immunotherapy biomarker candidates induced by cancer deformation
    Se Min Kim et al, 2024, PLoS ONE CrossRef
51. null
    Figen Abatay Sel et al, 2024 CrossRef